Multiple sclerosis
Molecular mimicry of an antimyelin HLA class I restricted T-cell receptor
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 20, 2016
- Accepted in final form April 1, 2016
- First Published May 17, 2016.
Author Disclosures
- Geraldine Rühl*,
- Anna G. Niedl, PhD*,
- Atanas Patronov, PhD,
- Katherina Siewert, PhD,
- Stefan Pinkert, PhD,
- Maria Kalemanov,
- Manuel A. Friese, MD,
- Kathrine E. Attfield, PhD,
- Iris Antes, PhD,
- Reinhard Hohlfeld, MD and
- Klaus Dornmair, PhD
- Geraldine Rühl*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anna G. Niedl, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Studienstiftung des Deutschen Volkes
NONE
NONE
NONE
NONE
NONE
NONE
- Atanas Patronov, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katherina Siewert, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stefan Pinkert, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Kalemanov,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Manuel A. Friese, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Research Foundation, German Ministry of Education and Research
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kathrine E. Attfield, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Iris Antes, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Reinhard Hohlfeld, MD and
Served on Scientific Advisory boards for Novartis; Biogen-Idec; Bayer-Schering; Merck-Serono; Sanofi-Aventis; Teva; Served on data safety monitoring boards for Novartis; Merck Serono (since 2007); CSL Behring; Medday; Actelion
NONE
Received funding for trips from Novartis; Biogen-Idec; Bayer-Schering; Merck-Serono; Sanofi-Aventis; Teva; Genzyme
Serve as editorial board member of Neurology (currently); Brain; Clinical and Experimental Immunology; Deutsche Medizinische Wochenschrift; Expert Opinion on Biological Therapy; Journal of Neuroimmunology; Multiple Sclerosis; Nervenarzt; Practical Neurology; Seminars in Immunopathology; Therapeutic Advances in Neurological Disorders
NONE
NONE
NONE
Receive consulting fees from Novartis; Biogen-Idec; Bayer-Schering; Merck-Serono; Sanofi-Aventis; Teva; Genzyme; Medday; Actelion
NONE
NONE
NONE
Received grant support from Novartis (2008 to present); Biogen-Idec (2005-2009); Bayer-Schering (2001-2006); Teva (1999-2007)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Klaus Dornmair, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Deutsche Forschungsgemeinschaft (Munich Cluster for Systems Neurology (EXC 1010 SyNergy), (2) Deutsche Forschungsgemeinschaft CRC-TR-128-A5, -128-A1, and -128-B8),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Institute of Clinical Neuroimmunology (G.R., A.G.N., K.S., R.H., K.D.) and Munich Cluster for Systems Neurology (SyNergy) (R.H., K.D.), Ludwig-Maximilian-University, Munich; Department of Life Sciences (A.P., M.K., I.A.), Technical University Munich, Freising; Max Planck Institute of Biochemistry (S.P.), Martinsried; Institute of Neuroimmunology and Multiple Sclerosis (M.A.F.), University Medical Centre, Hamburg-Eppendorf, Hamburg, Germany; MRC Human Immunology Unit (K.E.A.), Radcliffe Department of Medicine, Weatherall, Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, UK; and Center for Integrated Protein Science Munich (CIPSM) (I.A.), Germany.
- Correspondence to Dr. Dornmair: Klaus.Dornmair{at}med.uni-muenchen.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis
Dr. Robert Pitceathly and Dr. William Macken
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Cytokine Networks in Multiple Sclerosis
The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosisReinhard Hohlfeld, Edgar Meinl, Frank Weber et al.Neurology, June 01, 1995 -
Articles
Human T-cell response to myelin basic protein peptide (83-99): Extensive heterogeneity in antigen recognition, function, and phenotypeB. Hemmer, M. Vergelli, L. Tranquill et al.Neurology, October 01, 1997 -
Articles
Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosisSuhayl Dhib-Jalbut et al.Neurology, June 04, 2007 -
Article
Indictment of the microglia as the villain in multiple sclerosisS. Sriram, M. Rodriguez et al.Neurology, February 01, 1997